Transplant News and Research

RSS

Louisville Chief of Cardiovascular Medicine earns APS' Walter B. Cannon Award

Heart failure affects roughly six million Americans, yet treatment consists of either a heart transplant or the insertion of mechanical devices that assist the heart. This is unacceptable to Roberto Bolli, MD, Chief of the Division of Cardiovascular Medicine at the University of Louisville in Louisville, Ky., which is why he is on a mission to make cardiac stem cell treatment an option for all who must cope with the limitations of a failing heart.

11 Apr 2011

State News: N.Y. billing for disabled patients questioned

While the nation's attention has been focused on state worker battles in union strongholds such as Ohio and Wisconsin, quiet but consequential labor battles are breaking out in Kansas, Texas and other states where collective bargaining rights for public workers were weak or non-existent to begin with. The outcome of these confrontations will have a big impact.

8 Apr 2011

T2 Biosystems' technology platform demonstrates ability to detect Candida organisms in whole blood samples

T2 Biosystems, Inc., a company developing next-generation diagnostic products, presented data today on the rapid and sensitive detection of five species of the fungal infection Candida at the Annual Meeting of the Mycoses Study Group in Philadelphia, PA.

8 Apr 2011

Kidney transplantion more effective than previously thought

A new study from Mayo Clinic, the largest long-term study of kidney transplant recipients published to date, demonstrates that progressive damage to kidney transplants may be less common and less severe than previously reported.

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

Cenovus donates $1.3 million to Alberta Children's Hospital to combat childhood cancer

Cenovus Energy Inc. is proud to announce that the company has committed $1.3 million to the Alberta Children's Hospital Foundation to help experts at the Alberta Children's Hospital in the fight against childhood cancer.

8 Apr 2011

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Alexion Pharmaceuticals, Inc. announced today that the company has submitted marketing applications to the U.S. Food and Drug Administration and the European Medicines Agency for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

Viewpoints: Major news organizations on Ryan plan: Solution or 'hypocrisy'?

Give House Budget Committee Chairman Paul Ryan credit for finally putting Republicans' money where their mouths have been for years: His 2012 budget proposal, released Tuesday, would actually begin to produce the smaller government Republicans have always said they wanted, even as they were ramping up federal spending, creating a prescription drug benefit without paying for it, campaigning against efforts to curb Medicare, and turning budget surpluses into titanic deficits.

7 Apr 2011

Scientists identify biological pathways that mediate IgA nephropathy

For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

The Harvard Clinical Research Institute and Saint Luke's Mid America Heart and Vascular Institute today announced that Matthew R. Reynolds, M.D., Director of the Economics and Quality of Life Research Center at HCRI, presented results of a cost-effectiveness analysis of transcatheter aortic valve replacement versus standard therapy for severe aortic stenosis, as part of the opening plenary session on April 3 at the American College of Cardiology 60th Annual Scientific Session & Expo.

5 Apr 2011

Rare 5-way kidney swap transplant successful

All ten patients are doing well after a rare 5-way kidney swap transplant at California Pacific Medical Center in San Francisco, part of the Sutter Health network.

5 Apr 2011

All Children's Hospital joins Johns Hopkins Medicine

All Children's Hospital, in St. Petersburg, Fla., is now a part of the Johns Hopkins Health System (JHHS) and a fully integrated member of Johns Hopkins Medicine (JHM). All Children's is the first U.S. hospital outside of the Baltimore/Washington, D.C., region to become integrated with JHM, which includes the Johns Hopkins University School of Medicine and The Johns Hopkins Hospital and Health System.

4 Apr 2011

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Hospital admissions at Stony Brook University Medical Center on Long Island were significantly reduced when using coronary computed tomographic angiography (CCTA) to evaluate patients presenting in the emergency department (ED) with acute chest pain (ACP), according to research results presented during a scientific session at the American College of Cardiology's 60th Annual Scientific Session and Expo in New Orleans on April 3.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Cell Therapeutics, Inc. announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone in treating patients with aggressive non-Hodgkin's lymphoma who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone.

4 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

Transplant News and Research

Louisville Chief of Cardiovascular Medicine earns APS' Walter B. Cannon Award

State News: N.Y. billing for disabled patients questioned

T2 Biosystems' technology platform demonstrates ability to detect Candida organisms in whole blood samples

Kidney transplantion more effective than previously thought

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Cenovus donates $1.3 million to Alberta Children's Hospital to combat childhood cancer

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Viewpoints: Major news organizations on Ryan plan: Solution or 'hypocrisy'?

Scientists identify biological pathways that mediate IgA nephropathy

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

Rare 5-way kidney swap transplant successful

All Children's Hospital joins Johns Hopkins Medicine

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News